JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

Anna Sophia McKenney, … , Craig B. Thompson, Ross L. Levine

*J Clin Invest.* 2018;128(10):4743-4743. [https://doi.org/10.1172/JCI124920](https://doi.org/10.1172/JCI124920).

**Corrigendum**

Original citation: J Clin Invest. 2018;128(2):789–804. [https://doi.org/10.1172/JCI94516](https://doi.org/10.1172/JCI94516)

Citation for this corrigendum: J Clin Invest. 2018;128(10):4743. [https://doi.org/10.1172/JCI124920](https://doi.org/10.1172/JCI124920)

Craig B. Thompson’s conflict-of-interest statement was not included in the manuscript. The authors apologize for the oversight. The correct statement is below. CBT is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He also serves on the board of directors of Merck and Charles River Laboratories. The authors regret the error.

Find the latest version:

[http://jci.me/124920/pdf](http://jci.me/124920/pdf)
Corrigendum

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition


Citation for this corrigendum: J Clin Invest. 2018;128(10):4743. https://doi.org/10.1172/JCI124920.

Craig B. Thompson’s conflict-of-interest statement was not included in the manuscript. The authors apologize for the oversight. The correct statement is below.

CBT is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He also serves on the board of directors of Merck and Charles River Laboratories.

The authors regret the error.